Oncology Today with Dr Neil Love cover image

Management of HER2-Altered Non-Small Cell Lung Cancer

Oncology Today with Dr Neil Love

00:00

TDXD First Line Trials - What's the Difference?

I kind of get the feeling that the lung people aren't as concerned about it. We did a whole program where we work with a pulmonologist trying to dissect out the whole issue of ILD. Half of your colleagues right now would like to give TDXD first line. In terms of ILD, it's not benign. It could be certainly fatal. Our Destiny Lungo I trials had reported the fatality. So did most TDXD trials, except Destiny breast 03,. which gave it early line with extensive education and early intervention program that actually made the difference.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app